Immune checkpoint inhibitors (ICPis) re-challenge : outcomes analysisin a french national cohortof non small cell lung cancer (NSCLC) patients

Autor: Gobbini, E, giaj levra, m, Pérol, M, Chouaid, C, Duruisseaux, M, Bennouna, J, Gervais, R, Westeel, V, Mazieres, J, Guisier, F, Veillon, R, Zalcman, G, Giroux, E, vanel, fr, Wislez, M, Dansin, E, Descourt, R, Decroisette, C, Barlesi, F, Girard, N, Fournel, P, Planchard, D, Oulkhouir, Y, Cadranel, J, Duchemann, B, monier, o, Toffart, A, Moro-Sibilot, D

Publikováno v: World Conference on Lung Cancer
World Conference on Lung Cancer, Sep 2019, Barcelone, Spain

International audience

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::e708176ef96a2280bb298e51ec967d8e
https://hal.archives-ouvertes.fr/hal-02626447

Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.

Autor: Gobbini E; Thoracic Oncology Unit SHUPP, CHU Grenoble-Alpes, Grenoble, France; Cancer Research Center Lyon, Center Léon Bérard, Lyon, France. Electronic address: EGobbini@chu-grenoble.fr., Toffart AC; Thoracic Oncology Unit SHUPP, CHU Grenoble-Alpes, Grenoble, France., Pérol M; Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France., Assié JB; Thoracic Oncology Unit, CHU Créteil, Paris, France., Duruisseaux M; Unité de Recherche Commune en Oncologie Thoracique (URCOT), Hospices Civils de Lyon Cancer Institute, Lyon, France; Anticancer Antibodies Laboratory, Cancer Research Center of Lyon, Inserm 1052, CNRS 5286, Lyon, France; Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France., Coupez D; Thoracic Oncology Unit, CHU Nantes, Nantes, France., Dubos C; Thoracic Oncology Unit, Center François Baclesse, Caen, France., Westeel V; Thoracic Oncology Unit, CH Besançon, Besançon, France., Delaunay M; Pulmonology Department, CHU Toulouse, Toulouse, France., Guisier F; Pneumology, Thoracic Oncology, and Respiratory Intensive Care Unit, CHU Rouen, Rouen, France., Veillon R; Respiratory Diseases Department, F-33000, CHU Bordeaux, Bordeaux, France., Gounant V; Thoracic Oncology Department, CIC 1425 INSERM, Center Bichat, Paris, France., Giroux Leprieur E; Department of Respiratory Diseases and Thoracic Oncology, APHP-Hôpital Ambroise Pare, Paris, France., Vanel FR; Thoracic Oncology Unit, CHU Strasbourg, Strasbourg, France., Chaabane N; Pulmonology Service, AP-HP Paris Center University Hospitals, Cochin Hospital, Paris, France., Dansin E; Thoracic Oncology Unit, Center Oscar Lambret, Lille, France., Babey H; Thoracic Oncology Unit, CHRU Brest, Brest, France., Decroisette C; Pulmonology and Thoracic Oncology Unit, CH Annecy-Genevois, Annecy, France., Barlesi F; Aix-Marseille Université, CNRS, INSERM, CRCM, APHM, Marseille, France., Daniel C; Thoracic Oncology Unit, Institute Curie, Paris/Saint Cloud, France., Fournel P; Medical Oncology Department, Institut de Cancérologie de la Loire, Saint, France., Mezquita L; Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France., Oulkhouir Y; Pulmonology and Thoracic Oncology Unit, CHU Caen, Caen, France., Canellas A; Pulmonology Unit, APHP Hôpital Tenon and GRC 04 Theranoscan Sorbonne University, Paris, France., Duchemann B; Thoracic Oncology Unit, Center Bobigny, Paris, France., Molinier O; Thoracic Oncology Unit, CH Le Mans, Le Mans, France., Alcazer V; Cancer Research Center Lyon, Center Léon Bérard, Lyon, France., Moro-Sibilot D; Thoracic Oncology Unit SHUPP, CHU Grenoble-Alpes, Grenoble, France., Levra MG; Thoracic Oncology Unit SHUPP, CHU Grenoble-Alpes, Grenoble, France.

Publikováno v: Clinical lung cancer [Clin Lung Cancer] 2020 Sep; Vol. 21 (5), pp. e497-e510. Date of Electronic Publication: 2020 May 08.